Search

Displaying results 2951 - 2960 of 6835 in total
  1. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis. … CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  2. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases. … [L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.

  3. Drug

    Eptifibatide

    go.drugbank.com/drugs/DB00063
    ApprovedInvestigational

    Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. … Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.

  4. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. … Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.

  5. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation

    Synonyms: Ig heavy chain V-III region BUR
  6. Drug

    Indium In-111 pentetate

    go.drugbank.com/drugs/DB09425
    ApprovedInvestigational

    Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

  7. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    [A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin … [L51254] It is designed to deliver diphtheria toxin into IL-2 receptor-expressing cancer cells to cause cell death.

  8. Drug

    Zanamivir

    go.drugbank.com/drugs/DB00558
    ApprovedInvestigational

    A guanido-neuraminic acid that is used to inhibit neuraminidase.

  9. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. … Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.

  10. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.